Istradefylline

Introduction Overview

Generic Name

istradefylline

Brand Name

Nourianz

Dosage Form

Tablet

Drug Class

Miscellaneous antiparkinson agents

Pharmacokinetics

Absorption: Istradefylline, administered orally as Nourianz tablets, demonstrates rapid absorption through the gastrointestinal tract, with peak plasma concentrations generally reached within 4 hours post-dose. Its bioavailability is influenced modestly by food intake, though it can be administered with or without food. The presence of food does not significantly alter the extent of absorption, affording flexibility for patient dosing schedules. Clinical pharmacokinetic studies indicate a high degree of gastrointestinal tolerance and consistent plasma levels conducive to once-daily dosing.

Distribution: Following absorption, istradefylline exhibits extensive distribution throughout body tissues, characterized by a large volume of distribution (approximately 160 liters), indicating substantial tissue penetration. The drug exhibits high plasma protein binding (~99%), primarily to albumin and alpha-1 acid glycoprotein, which influences its pharmacodynamics and interaction potential. Penetration through the blood-brain barrier is critical for its therapeutic efficacy in Parkinson's disease, with sufficient central nervous system (CNS) bioavailability documented in preclinical and clinical assessments.

Metabolism: Istradefylline undergoes extensive hepatic metabolism predominantly via cytochrome P450 enzymes, specifically CYP1A1 and CYP3A4 isoforms. The metabolic pathways include oxidation and subsequent conjugation, leading to various inactive metabolites. The metabolism is subject to interindividual variability, influenced by genetic polymorphisms and exposure to enzyme inducers or inhibitors. Given its metabolism, concomitant use of drugs that inhibit or induce CYP3A4 can substantially alter istradefylline plasma concentrations, necessitating careful monitoring.

Elimination: The elimination half-life of istradefylline approximates 83 hours, supporting once-daily administration. The drug and its metabolites are primarily excreted via feces (~70%) with minor urinary elimination (~10%). Renal clearance plays a limited role in drug elimination. The prolonged half-life reflects extensive tissue binding and slow release, contributing to sustained pharmacological effects. Dose adjustments are generally not required in mild to moderate renal impairment; however, caution is advised in severe hepatic dysfunction given the hepatic metabolism and excretion profile.

Dosage Forms

Available Dosage Forms: Nourianz is supplied exclusively as oral tablets with two available strengths to accommodate individualized dosing. The tablets are:
- 20 mg oral tablet
- 40 mg oral tablet

Dosages for Adults and Adolescents: In Parkinson's disease patients experiencing OFF episodes, Nourianz is initiated at 20 mg orally once daily, preferably at the same time each day. Based on clinical response and tolerability, the dose may be increased to a maximum of 40 mg once daily. There is no indication for use in pediatric populations, and dosing regimens have been well established for adult patients only.

Specific Patient Populations: Dose adjustments based on hepatic or renal impairment are not typically necessary in mild to moderate dysfunction. However, in patients with underlying liver disease, clinical caution is warranted due to the hepatic metabolism of istradefylline. There is limited data regarding use in pregnant or breastfeeding women, underscoring the importance of evaluating risk-benefit on a case-by-case basis. The elderly population does not require specific dosage modifications but should be monitored for adverse effects due to possible increased sensitivity.

Mechanism Of Action

Istradefylline, the active ingredient in Nourianz, functions primarily as a selective antagonist of the adenosine A2A receptor subtype. Adenosine receptors are G protein-coupled receptors that modulate numerous neurotransmitter systems in the central nervous system, particularly within the basal ganglia, a brain region critically involved in motor control. In Parkinson’s disease, dysregulation of dopaminergic pathways leads to motor symptoms; istradefylline's selective blockade of A2A receptors alleviates these symptoms by modulating neuronal activity.

The A2A receptors are located predominantly on the GABAergic medium spiny neurons of the indirect pathway within the striatum. By antagonizing these receptors, istradefylline influences the balance between excitatory and inhibitory neurotransmission, facilitating enhanced dopaminergic signaling indirectly. This results in improved motor function, particularly by reducing OFF episodes characterized by bradykinesia and rigidity.

At the molecular level, A2A receptor antagonism by istradefylline mitigates the inhibitory effects of adenosine on dopamine D2 receptor-expressing neurons, leading to increased cAMP signaling and downstream effects that restore normal motor output. Clinical studies have demonstrated that adjunctive therapy with istradefylline alongside levodopa/carbidopa reduces the duration and severity of OFF episodes, emphasizing its role in supplementing dopaminergic treatments.

Comparatively, unlike dopamine agonists or MAO-B inhibitors, istradefylline acts on a non-dopaminergic pathway, targeting adenosine receptor-mediated modulation. This unique mechanism offers complementary benefits with a distinct side effect profile, making it a valuable adjunct in complex Parkinson’s disease management. Research continues to elucidate its broader neuroprotective potentials and effects on non-motor symptoms of Parkinson's disease.

Pharmacological Actions

Selective antagonism of adenosine A2A receptors in the central nervous system
Modulation of striatal GABAergic output to enhance motor control
Adjunctive anti-Parkinsonian activity reducing OFF periods in levodopa-treated patients
Improved dopaminergic neurotransmission via indirect pathway modulation
Reduction of motor complications associated with long-term levodopa therapy
Minimal direct dopaminergic receptor interaction, lowering risk of dopaminergic adverse events
Potential normalization of basal ganglia circuitry impaired in Parkinson’s disease
Contribution to improved quality of life by reducing motor fluctuations
Possible influence on neuroinflammatory pathways through adenosine receptor modulation
Extended half-life enabling once-daily dosing with stable pharmacodynamic effect
No significant anticholinergic activity
Lack of significant sedative properties
Diminished risk of orthostatic hypotension compared to dopamine agonists
Adjunctive synergy with levodopa/carbidopa enhancing overall therapeutic efficacy

Therapeutic Or Clinical Uses

Adjunctive treatment to levodopa/carbidopa in adults with Parkinson’s disease to reduce OFF episodes
Management of motor fluctuations characterized by wearing-off phenomena in Parkinson’s disease
Improvement of motor symptoms such as bradykinesia and muscle stiffness during OFF periods
Reduction of Parkinson’s disease-related motor variability in advanced stages
Adjunct therapy to optimize dopaminergic treatment in fluctuating Parkinsonian patients
Therapeutic option for patients experiencing suboptimal control on levodopa alone
Potential use in patients who are intolerant to increasing levodopa doses
Enhancement of daily motor function facilitating improved activities of daily living
Alternative mechanism of action providing complementary benefits to dopamine-centric therapies
Treatment incorporated into comprehensive Parkinson’s disease management plans

Side Or Adverse Effects

Involuntary muscle movements (dyskinesia) potentially exacerbated with dosage increases
Hallucinations, particularly visual, more frequent in elderly or patients with psychiatric history
Dizziness and vertigo, which may impact balance and increase fall risk
Nausea and constipation as gastrointestinal side effects
Sleep disturbances including insomnia
Potential development of new or worsening psychiatric symptoms such as confusion or impulsivity
Risk of abnormal or uncontrollable muscle movements necessitating clinical monitoring
Possible intensity of sexual urges or compulsive behaviors including gambling and other risk-taking activities
Allergic reactions such as urticaria or swelling are rare but require immediate medical attention
Postural hypotension is uncommon but should be considered especially in predisposed individuals
Fatigue or somnolence reported in some patients
Headache occasionally observed
Dry mouth and related symptoms infrequently reported
Rare cases of liver function abnormalities have been documented
Exacerbation of pre-existing psychosis in vulnerable patients

Precautions

Use caution in patients with a history of abnormal involuntary muscle movements
Monitor for emergence or worsening of psychiatric symptoms including hallucinations and psychosis
Assess liver function prior to and during treatment in patients with existing hepatic disease
Cautious use recommended in smokers due to possible CYP1A1 induction altering drug metabolism
Consider risks versus benefits in elderly patients who may be more vulnerable to side effects
Evaluate mental health status before initiation due to risk of impulsive behaviors or hallucinations
Advise patients about the potential for increased urges such as gambling or sexual behaviors
Avoid sudden discontinuation to prevent exacerbation of Parkinsonian symptoms
Monitor for signs of serotonin syndrome if combined with serotonergic agents
Inform patients to report any new or worsening psychiatric symptoms promptly
Use during pregnancy only if potential benefit justifies potential risk; breastfeeding safety undetermined
Ensure patients understand dosing schedule to minimize risk of overdose or missed doses
Patients with severe liver impairment should be treated with caution due to unknown safety profile
Avoid concurrent use with strong CYP3A4 inhibitors without dose adjustment
Evaluate for drug interactions prior to initiation

Warnings

Risk of uncontrolled or involuntary muscle movements such as dyskinesia
Potential for hallucinations, particularly in elderly or patients with psychiatric disorders
Possibility of increased risk-taking behavior and impulse control disorders, including gambling addiction
Allergic reactions including anaphylaxis require immediate medical evaluation
Not recommended in patients with a history of psychosis or severe psychiatric conditions
May exacerbate mental illness or cause unusual thoughts or behavior
Risk of dizziness that may contribute to falls, especially in frail individuals
Use with caution in patients with liver impairment due to metabolic considerations
Avoid overdose as it may increase adverse events; no known antidote available
Potential for confusion or hallucinations necessitating caregiver vigilance
Monitor for signs of serotonin syndrome when combined with serotonergic drugs
Increased sexual and gambling urges require patient and caregiver awareness
Safety and efficacy not established in pediatric population
Pregnancy and breastfeeding use only if clearly needed and under medical supervision
Ensure proper storage and keep out of reach of children to prevent accidental ingestion

Contraindication

Known hypersensitivity or allergy to istradefylline or any components of the formulation
History of severe psychosis or uncontrolled psychiatric illness
Concurrent use with strong CYP3A4 inhibitors without appropriate dose adjustment
Patients with severe hepatic impairment due to insufficient safety data
Individuals with a history of severe involuntary movements unmanageable by clinical intervention
Hypersensitivity reactions to similar adenosine receptor antagonists
Use contraindicated in pediatric patients due to lack of safety and efficacy data
Conditions causing significant compromised blood-brain barrier function
Patients unable to comply with dosing or monitoring requirements
Uncontrolled cardiovascular disease complicating Parkinson’s management
Pregnancy and breastfeeding contraindicated unless benefits outweigh risks as advised by physician
Known alcohol intolerance due to potential additive neurological effects
Concomitant use with other adenosine receptor antagonists is contraindicated
Severe renal impairment without adequate clinical monitoring
History of severe drug-induced liver injury

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase istradefylline plasma levels, increasing risk of adverse effects
CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease istradefylline efficacy by lowering plasma concentration
Concurrent use with levodopa/carbidopa enhances antiparkinsonian effect but can potentiate dyskinesias
Avoid concomitant use with other adenosine receptor antagonists due to additive pharmacologic effects
Potential interactions with serotonin reuptake inhibitors increasing risk for serotonin syndrome
Drugs affecting central nervous system functions may have additive side effects, e.g., antipsychotics
Smoking induces CYP1A1 and may increase istradefylline metabolism, reducing therapeutic efficacy
May interact with drugs affecting cardiac conduction requiring ECG monitoring
Herbal supplements such as St. John's Wort may induce CYP enzymes altering drug levels
Vitamins and over-the-counter medications should be reviewed for potential interactions
Monoamine oxidase inhibitors (MAOIs) co-administration requires caution due to altered neurotransmitter dynamics
Concomitant use with other antiparkinsonian agents necessitates monitoring for enhanced side effects
Use with strong CYP1A1 inhibitors may increase drug exposure
Drugs that influence gastrointestinal motility may alter absorption kinetics of istradefylline
Potential alteration of plasma protein binding by other highly protein-bound drugs

Preparations Of The Drug

Available as 20 mg oral tablets for once-daily administration
Available as 40 mg oral tablets to allow dose escalation as per clinical need
Tablets are film-coated for ease of swallowing and masking taste
Supplied in blister packs or bottles with appropriate child-resistant packaging
No known injectable or alternative formulations currently marketed
Stored at room temperature, protected from moisture and heat
Packaging includes detailed patient information and dosing instructions
Prescribed strictly on physician authorization with dosage titration as needed
Formulated for stability and consistent bioavailability
Bulk formulations for compounding are not commercially available
Not formulated as extended-release; designed for immediate release with prolonged half-life
No known oral liquid or dispersible tablet forms currently approved
Provided with accompanying Medication Guides per regulatory requirements
Parenteral or transdermal forms under research but not yet approved
Manufactured under Good Manufacturing Practices ensuring quality and potency